Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 25;13(12):1132.
doi: 10.3390/antibiotics13121132.

Infective Endocarditis by Biofilm-Producing Methicillin-Resistant Staphylococcus aureus-Pathogenesis, Diagnosis, and Management

Ashlesha Kaushik  1 , Helen Kest  2 , Mangla Sood  3 , Corey Thieman  4 , Bryan W Steussy  5 , Michael Padomek  4 , Sandeep Gupta  6
Affiliations
Review

Infective Endocarditis by Biofilm-Producing Methicillin-Resistant Staphylococcus aureus-Pathogenesis, Diagnosis, and Management

Ashlesha Kaushik et al. Antibiotics (Basel). .

Abstract

Infective endocarditis (IE) is a life-threatening condition with increasing global incidence, primarily caused by Staphylococcus aureus, especially methicillin-resistant strains (MRSA). Biofilm formation by S. aureus is a critical factor in pathogenesis, contributing to antimicrobial resistance and complicating the treatment of infections involving prosthetic valves and cardiovascular devices. Biofilms provide a protective matrix for MRSA, shielding it from antibiotics and host immune defenses, leading to persistent infections and increased complications, particularly in cases involving prosthetic materials. Clinical manifestations range from acute to chronic presentations, with complications such as heart failure, embolic events, and neurological deficits. Diagnosis relies on the Modified Duke Criteria, which have been updated to incorporate modern cardiovascular interventions and advanced imaging techniques, such as PET/CT (positron emission tomography, computed tomography), to improve the detection of biofilm-associated infections. Management of MRSA-associated IE requires prolonged antimicrobial therapy, often with vancomycin or daptomycin, needing a combination of antimicrobials in the setting of prosthetic materials and frequently necessitates surgical intervention to remove infected prosthetic material or repair damaged heart valves. Anticoagulation remains controversial, with novel therapies like dabigatran showing potential benefits in reducing thrombus formation. Despite progress in treatment, biofilm-associated resistance poses ongoing challenges. Emerging therapeutic strategies, including combination antimicrobial regimens, bacteriophage therapy, antimicrobial peptides (AMPs), quorum sensing inhibitors (QSIs), hyperbaric oxygen therapy, and nanoparticle-based drug delivery systems, offer promising approaches to overcoming biofilm-related resistance and improving patient outcomes. This review provides an overview of the pathogenesis, current management guidelines, and future directions for treating biofilm-related MRSA IE.

Keywords: MRSA; antibiotics; biofilm; infective endocarditis; methicillin-resistant Staphylococcus aureus; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Stages in biofilm formation in MRSA IE. Stages are represented in orange boxes. Facilitating factors for each stage are shown in yellow boxes.
Figure 2
Figure 2
Schematic representation of treatments for native valve and prosthetic valve MRSA IE [1,2].
Figure 2
Figure 2
Schematic representation of treatments for native valve and prosthetic valve MRSA IE [1,2].
See this image and copyright information in PMC

References

    1. Baddour L.M., Wilson W.R., Bayer A.S., Fowler V.G., Jr., Tleyjeh I.M., Rybak M.J., Barsic B., Lockhart P.B., Gewitz M.H., Levison M.E., et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132:1435–1486. doi: 10.1161/CIR.0000000000000296. Erratum in: Circulation 2015, 132, e215. https://doi.org/10.1161/CIR.0000000000000332. Erratum in: Circulation 2016, 134, e113. https://doi.org/10.1161/CIR.0000000000000427. Erratum in: Circulation 2018, 138, e78–e79. https://doi.org/10.1161/CIR.0000000000000594. - DOI - PubMed
    1. Delgado V., Ajmone Marsan N., de Waha S., Bonaros N., Brida M., Burri H., Caselli S., Doenst T., Ederhy S., Erba P.A., et al. 2023 ESC Guidelines for the management of endocarditis. Eur. Heart J. 2023;44:3948–4042. doi: 10.1093/eurheartj/ehad193. Erratum in: Eur. Heart J. 2023, 44, 4780. https://doi.org/10.1093/eurheartj/ehad625. Erratum in: Eur. Heart J. 2024, 45, 56. https://doi.org/10.1093/eurheartj/ehad776. - DOI - PubMed
    1. Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., Ezzati M., Shibuya K., Salomon J.A., Abdalla S., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–2223. doi: 10.1016/S0140-6736(12)61689-4. Erratum in: Lancet 2013, 381, 628. - DOI - PubMed
    1. Shah A.S.V., McAllister D.A., Gallacher P., Astengo F., Rodríguez Pérez J.A., Hall J., Lee K.K., Bing R., Anand A., Nathwani D., et al. Incidence, Microbiology, and Outcomes in Patients Hospitalized with Infective Endocarditis. Circulation. 2020;141:2067–2077. doi: 10.1161/CIRCULATIONAHA.119.044913. Erratum in: Circulation 2020, 141, e960. https://doi.org/10.1161/CIR.0000000000000879. - DOI - PMC - PubMed
    1. Østergaard L., Lauridsen T.K., Iversen K., Bundgaard H., Søndergaard L., Ihlemann N., Moser C., Fosbøl E. Infective endocarditis in patients who have undergone transcatheter aortic valve implantation: A review. Clin. Microbiol. Infect. 2020;26:999–1007. doi: 10.1016/j.cmi.2020.01.028. - DOI - PubMed

LinkOut - more resources